NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 130 filers reported holding NURIX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,761,880 | +256420.5% | 324,000 | +80.7% | 0.01% | +175.0% |
Q1 2024 | $2,636 | +121.7% | 179,300 | +55.6% | 0.00% | +100.0% |
Q4 2023 | $1,189 | +463.5% | 115,200 | +329.9% | 0.00% | – |
Q3 2023 | $211 | -17.9% | 26,800 | -7.3% | 0.00% | – |
Q1 2023 | $257 | -80.3% | 28,900 | -75.7% | 0.00% | -100.0% |
Q4 2022 | $1,303 | -99.9% | 118,700 | +61.9% | 0.00% | +100.0% |
Q3 2022 | $955,000 | -36.3% | 73,300 | -38.1% | 0.00% | -50.0% |
Q2 2022 | $1,500,000 | +40.4% | 118,400 | +55.4% | 0.00% | +100.0% |
Q1 2022 | $1,068,000 | – | 76,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP III, LLC | 3,422,549 | $90,800,000 | 15.85% |
Ponoi II Management, LLC | 686,274 | $18,207,000 | 14.76% |
Ponoi Management, LLC | 686,274 | $18,207,000 | 10.12% |
Foresite Capital Management V, LLC | 451,522 | $11,979,000 | 4.71% |
Foresite Capital Management IV, LLC | 1,205,798 | $31,990,000 | 4.32% |
Bain Capital Life Sciences Investors, LLC | 1,284,314 | $34,073,000 | 2.23% |
EcoR1 Capital, LLC | 1,967,950 | $52,210,000 | 1.95% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $15,155,000 | 1.93% |
DAFNA Capital Management LLC | 306,320 | $8,127,000 | 1.70% |
Euclidean Capital LLC | 154,426 | $4,097,000 | 1.33% |